The evolving role of cytoreductive nephrectomy: Incorporating genomics of metastatic renal cell carcinoma into treatment decisions

Keyphrases

• Angiogenic 20%
• Chromatin Remodeling Genes 20%
• Clinical Applicability 20%
• Cytoreductive Nephrectomy 100%
• Effector Genes 20%
• Evolving Roles 100%
• Gene Signature 20%
• Gene Single nucleotide Polymorphism 20%
• Genetic Modification 40%
• Genetic Outcome 20%
• Growth Factor Pathway 20%
• High-level Expression 20%
• Improved Outcomes 40%
• Mammalian Target of Rapamycin (mTOR) 20%
• Metastatic Renal Cell Carcinoma (mRCC) 100%
• Metastatic Tumor 20%
• MTOR Inhibitor 20%
• Multiple Sites 20%
• Pathway mutation 20%
• Patient Selection 20%
• PBRM1 20%
• PBRM1 mutation 20%
• Predictive Role 20%
• Primary Tumor 40%
• PTEN Expression 20%
• Rapid Progression 20%
• Response to Immunotherapy 20%
• Somatic Copy number Alterations 20%
• Somatic mutation 20%
• Systemic Treatment 20%
• Targeted Therapy 40%
• Treatment Decisions 100%
• Treatment Timing 20%
• TSC1 20%
• TSC2 mutation 20%
• Tumor Heterogeneity 40%
• Vascular Endothelial Growth Factor 40%

Medicine and Dentistry

• Chromatin Remodeling 20%
• Gene Mutation 40%
• Immunotherapy 20%
• Kidney Metastasis 100%
• Mammalian Target of Rapamycin Inhibitor 20%
• Mechanistic Target of Rapamycin 20%
• Metastatic Carcinoma 20%
• Nephrectomy 100%
• Patient Selection 20%
• Primary Tumor 40%
• Single Nucleotide Polymorphism 20%
• Somatic Mutation 20%
• Somatics 20%
• Systemic Therapy 20%
• Targeted Therapy 40%
• Vasculotropin 40%